EUVIMEDEUVIMED entdecken
Open Access

Short-acting β2-agonist prescription patterns and clinical outcomes in Malaysia: A nationwide cohort of the SABINA III study

Andrea Yu-Lin Ban, Paranthaman Vengadasalam, Sri Wahyu Taher, Mohd Arif Mohd Zim, Syazatul Syakirin Sirol Aflah, Ummi Nadira Daut, Irfhan Ali Hyder Ali, Lalitha Pereirasamy, Azza Omar, Aishah Ibrahim, Noor Aliza Mohd Tarekh, Swee Kim Chan und 7 weitere

Malaysian Family Physician · 16.05.2023 · 18 · 32

DOI: 10.51866/oa.258 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Malaysian Family Physician, online erschienen am 16.05.2023. Verfasst von Andrea Yu-Lin Ban und 18 weiteren Autor:innen. Beteiligte Einrichtung: MB Bch BAO (Ireland), MMed (UKM), Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, Kuala Lum…. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

SABINA III assessed short-acting β2-agonist (SABA) prescription patterns and their association with asthma-related outcomes globally. Herein, we examined SABA prescription and clinical outcomes in the Malaysian cohort of SABINA III.

Methods

In this observational, cross-sectional study, patients (≥12 years) were recruited between July and December 2019 from 15 primary and specialty care centres in Malaysia. Prescribed asthma treatments and severe exacerbation history within 12 months prior and asthma symptom control during the study visit were evaluated. Associations of SABA prescription with asthma control and severe exacerbation were analysed using multivariable regression models.

Results

Seven hundred thirty-one patients (primary care, n=265 [36.3%]; specialty care, n=466 [63.7%]) were evaluated. The prevalence of SABA over-prescription (≥3 SABA prescriptions/year) was 47.4% (primary care, 47.1%; specialty care, 47.6%), 51.8% and 44.5% among all patients and patients with mild and moderate-to-severe asthma, respectively. Altogether 9.0% (n=66) purchased SABA without a prescription; among them, 43.9% (n=29) purchased ≥3 inhalers. The mean (standard deviation) number of severe asthma exacerbations was 1.38 (2.76), and 19.7% (n=144) and 25.7% (n=188) had uncontrolled and partly controlled symptoms, respectively. Prescriptions of ≥3 SABA inhalers (vs 1–2) were associated with lower odds of at least partly controlled asthma (odds ratio=0.42; 95% confidence interval [CI]=0.27–0.67) and higher odds of having severe exacerbation(s) (odds ratio=2.04; 95% CI=1.44–2.89).

Conclusion

The prevalence of SABA over-prescription in Malaysia is high, regardless of the prescriber type, emphasising the need for healthcare providers and policymakers to adopt latest evidence-based recommendations to address this public health concern.

Schlagwörter

Stichwörter der Autor:innen

AsthmaAsthma controlMalaysiaSevere exacerbationsShort-acting β2-agonist

Autor:innen und Institutionen

  • MB Bch BAO (Ireland), MMed (UKM), Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, Kuala Lumpur, Malaysia. Email: andreaban@gmail.com.
  • MBBS (UM), MMed (UM), Klinik Kesihatan Greentown, Jalan Raja Musa Aziz, Ipoh, Perak, Malaysia.
  • MBChB (Glasgow), MMed (UKM), Klinik Kesihatan Simpang Kuala, Jalan Kuala Kedah, Simpang Kuala, Alor Star, Kedah Darul Aman, Malaysia.
  • MB BCh BAO (Ireland), MMed (UM), KPJ Damansara Specialist Hospital 2, Bukit Lanjan, Kuala Lumpur, Malaysia.
  • MD (UKM), MRCP (UK), Institut Perubatan Respiratori, Jalan Pahang Kuala Lumpur, Kuala Lumpur, Malaysia.
  • MD (USM), MMed (UKM), Universiti Putra Malaysia, Jalan Universiti 1, Serdang, Selangor Darul Ehsan, Malaysia.

Zitieren

APA

Ban, A. Y., Vengadasalam, P., Taher, S. W., Mohd Zim, M. A., Sirol Aflah, S. S., Daut, U. N., Hyder Ali, I. A., Pereirasamy, L., Omar, A., Ibrahim, A., Mohd Tarekh, N. A., Chan, S. K., Ali, N., Mohd Isa, N. A., Hussain, H., Abdul Karim, N., Raja Gopal, V., Chiam, S. Y., & Beekman, M. J. H. I. (2023). Short-acting β2-agonist prescription patterns and clinical outcomes in Malaysia: A nationwide cohort of the SABINA III study. Malaysian Family Physician, 18, 32. https://doi.org/10.51866/oa.258

Vancouver

Ban AY, Vengadasalam P, Taher SW, Mohd Zim MA, Sirol Aflah SS, Daut UN, et al. Short-acting β2-agonist prescription patterns and clinical outcomes in Malaysia: A nationwide cohort of the SABINA III study. Malaysian Family Physician. 2023;18:32. doi:10.51866/oa.258

BibTeX
@article{Ban2023,
  author = {Ban, Andrea Yu-Lin and Vengadasalam, Paranthaman and Taher, Sri Wahyu and Mohd Zim, Mohd Arif and Sirol Aflah, Syazatul Syakirin and Daut, Ummi Nadira and Hyder Ali, Irfhan Ali and Pereirasamy, Lalitha and Omar, Azza and Ibrahim, Aishah and Mohd Tarekh, Noor Aliza and Chan, Swee Kim and Ali, Norsiah and Mohd Isa, Nor Azila and Hussain, Husni and Abdul Karim, Noraziah and Raja Gopal, Vieshal and Chiam, Sue Yin and Beekman, Maarten J H I},
  title = {Short-acting β2-agonist prescription patterns and clinical outcomes in Malaysia: A nationwide cohort of the SABINA III study},
  journal = {Malaysian Family Physician},
  year = {2023},
  volume = {18},
  pages = {32},
  doi = {10.51866/oa.258}
}
Kostenlos starten →